title: Liver transplantation for viral hepatitis: the experience of the hepatobiliary center at Hospital Paul Brousse.
abstract: The prevalence of HBV recurrence after liver transplantation is higher in patients with viral B cirrhosis than in patients with viral B-D cirrhosis or fulminant hepatitis B and is related to the presence of HBV replication prior to transplantation. Long-term passive anti-HBs immunoprophylaxis is the best current way for prevention of HBV reinfection and improved long-term survival. The rate of recurrence of HCV infection is high, reaching 85%, and the rate of HCV hepatitis in the graft is approximately 75%. In most cases, HCV hepatitis leads to chronic hepatitis. The severity of graft hepatitis is related to the level of viremia at the time of the hepatitis and to the genotype 1b. The methods of prevention of HCV infection after liver transplantation are yet to be found. The treatment of graft HCV infection with interferon should be well evaluated and given cautiously. Other antiviral treatments without an immunostimulating effect are needed. Finally, patients transplanted for hepatitis B without HBV replication, receiving posttransplant long-term anti-HBs immunoprophylaxis, and those transplanted for HCV cirrhosis have a 5-year survival similar to other groups of transplanted patients. Patients belonging to these groups can be considered as candidates for transplantation. Patients with active HBV replication should be included in specific trials for prevention of HBV reinfection.
authors.affiliation: Hepatobiliary Center, Paris South University, Hôpital Paul Brousse, Villejuif, France.
authors.forename: D
authors.initials: D
authors.lastname: Samuel
authors.forename: C
authors.initials: C
authors.lastname: Feray
authors.forename: H
authors.initials: H
authors.lastname: Bismuth
mesh_terms: D000206:Actuarial Analysis; D000998:Antiviral Agents / Q000627:therapeutic use; D005602:France / Q000453:epidemiology; D006509:Hepatitis B / Q000453:epidemiology / Q000601:surgery / Q000628:therapy; D006510:Hepatitis B Antibodies / Q000008:administration & dosage; D006515:Hepatitis B virus / Q000502:physiology; D006526:Hepatitis C / Q000453:epidemiology / Q000601:surgery; D006521:Hepatitis, Chronic / Q000453:epidemiology / Q000601:surgery; D006525:Hepatitis, Viral, Human / Q000453:epidemiology / Q000601:surgery*; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D007116:Immunization, Passive; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000601:surgery; D016031:Liver Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D007372:Interferons